Scholar Rock Narrows Losses but Faces Key Regulatory Milestones in 2026
Event summary
- Scholar Rock reported a net loss of $91.0 million for Q4 2025, narrowing from $66.5 million in Q4 2024.
- The company secured a new debt facility worth up to $550 million from Blue Owl Capital to support apitegromab commercialization.
- FDA completed a constructive meeting with Catalent Indiana regarding remediation progress, with no additional corrective actions requested.
- EMA decision on the apitegromab Marketing Authorisation Application is expected in mid-2026, with European launch planned for H2 2026.
The big picture
Scholar Rock is navigating a critical phase in its journey to commercialize apitegromab, with regulatory milestones in both the U.S. and Europe shaping its near-term prospects. The company's ability to secure non-dilutive capital underscores investor confidence in its pipeline, but execution risks remain high as it prepares for potential approvals and launches. The broader biopharmaceutical landscape is watching closely, particularly in the neuromuscular disease space where competitive dynamics and regulatory pathways are evolving rapidly.
What we're watching
- Regulatory Approval
- The pace at which Scholar Rock can resubmit and secure FDA approval for apitegromab following the reinspection of Catalent Indiana.
- Commercialization Strategy
- How Scholar Rock will leverage its $550 million debt facility to support the U.S. and European launches of apitegromab.
- Pipeline Advancement
- The progress of the Phase 2 FORGE trial for facioscapulohumeral muscular dystrophy (FSHD) and the development of SRK-439.